Lexington, KENTUCKY8 Active Studies

Spinal Muscular Atrophy Clinical Trials in Lexington, KENTUCKY

Find 8 actively recruiting spinal muscular atrophy clinical trials in Lexington, KENTUCKY. Connect with local research sites and explore new treatment options.

8
Active Trials
5
Sponsors
2,250
Enrolling

Recruiting Spinal Muscular Atrophy Studies in Lexington

RecruitingLexington, KENTUCKYNCT07063745

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus p...

590 participants
Bristol-Myers Squibb
View Study Details
RecruitingLexington, KENTUCKYNCT06203210

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC)....

540 participants
Daiichi Sankyo
View Study Details
RecruitingLexington, KENTUCKYNCT04165070

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-04...

450 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingLexington, KENTUCKYNCT05142696

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of t...

200 participants
Novartis Pharmaceuticals
View Study Details
RecruitingLexington, KENTUCKYNCT05882058

DAREONâ„¢-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard tre...

174 participants
Boehringer Ingelheim
View Study Details
RecruitingLexington, KENTUCKYNCT04938817

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1...

110 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingLexington, KENTUCKYNCT06780085

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body....

96 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingLexington, KENTUCKYNCT06731907

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical rem...

90 participants
Merck Sharp & Dohme LLC
View Study Details

About Spinal Muscular Atrophy Clinical Trials in Lexington

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 8 spinal muscular atrophy clinical trials recruiting participants in Lexington, KENTUCKY. These studies are seeking a combined 2,250 participants. Research is being sponsored by Bristol-Myers Squibb, Daiichi Sankyo, Merck Sharp & Dohme LLC and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Lexington — FAQ

Are there spinal muscular atrophy clinical trials in Lexington?

Yes, there are 8 spinal muscular atrophy clinical trials currently recruiting in Lexington, KENTUCKY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Lexington?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lexington research site will contact you about next steps.

Are clinical trials in Lexington free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lexington studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 8 active trials in Lexington are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov